OBJECTIVE: To assess the effect of pol replication capacity (RC) on the hazard ratio of progression to a composite endpoint of time to progression to <350 CD4+ cells per microliter, initiation of therapy, or death. METHODS: pol RC assays were performed after study closure in baseline samples obtained from 316 enrollees in a prospectively monitored cohort of treatment-naive adults with >or=450 CD4+ cells per microliter and >or=1000 HIV-1 RNA copies per milliliter. RESULTS: The median RC was 79%. Patients with a lower RC had a lower median viral load (4.0 vs 4.2 Log HIV-1 RNA copies/mL, P = 0.026) and a lower rate of protease inhibitor resistance 2% vs 8%, P = 0.03). Otherwise, baseline demographic and laboratory characteristics were similar. The hazard ratio of progression to the composite endpoint was 0.73 (P = 0.041) for persons with lower RC, 2.07 per 1.0 log10 higher viral load (P < 0.001), and 0.86 per 50 cells per microliter higher CD4+ cell count (P < 0.001). The effect of lower RC was also significant in a separate analysis of time to initiation of therapy (P = 0.04). CONCLUSIONS: These results show that untreated patients with lower vs higher RC had a slower rate of progression as assessed by a composite outcome of time to CD4+ count <or=350 cells per microliter, treatment initiation, or death.
OBJECTIVE: To assess the effect of pol replication capacity (RC) on the hazard ratio of progression to a composite endpoint of time to progression to <350 CD4+ cells per microliter, initiation of therapy, or death. METHODS: pol RC assays were performed after study closure in baseline samples obtained from 316 enrollees in a prospectively monitored cohort of treatment-naive adults with >or=450 CD4+ cells per microliter and >or=1000 HIV-1 RNA copies per milliliter. RESULTS: The median RC was 79%. Patients with a lower RC had a lower median viral load (4.0 vs 4.2 Log HIV-1 RNA copies/mL, P = 0.026) and a lower rate of protease inhibitor resistance 2% vs 8%, P = 0.03). Otherwise, baseline demographic and laboratory characteristics were similar. The hazard ratio of progression to the composite endpoint was 0.73 (P = 0.041) for persons with lower RC, 2.07 per 1.0 log10 higher viral load (P < 0.001), and 0.86 per 50 cells per microliter higher CD4+ cell count (P < 0.001). The effect of lower RC was also significant in a separate analysis of time to initiation of therapy (P = 0.04). CONCLUSIONS: These results show that untreated patients with lower vs higher RC had a slower rate of progression as assessed by a composite outcome of time to CD4+ count <or=350 cells per microliter, treatment initiation, or death.
Entities:
Keywords:
HIV infections; disease progression; natural history; replication
Authors: J C Learmont; A F Geczy; J Mills; L J Ashton; C H Raynes-Greenow; R J Garsia; W B Dyer; L McIntyre; R B Oelrichs; D I Rhodes; N J Deacon; J S Sullivan Journal: N Engl J Med Date: 1999-06-03 Impact factor: 91.245
Authors: Eric S Daar; Karen L Kesler; Terri Wrin; Christos J Petropoulo; Michael Bates; Alice Lail; Nicholas S Hellmann; Edward Gomperts; Sharyne Donfield Journal: AIDS Date: 2005-06-10 Impact factor: 4.177
Authors: C J Petropoulos; N T Parkin; K L Limoli; Y S Lie; T Wrin; W Huang; H Tian; D Smith; G A Winslow; D J Capon; J M Whitcomb Journal: Antimicrob Agents Chemother Date: 2000-04 Impact factor: 5.191
Authors: Benigno Rodríguez; Ajay K Sethi; Vinay K Cheruvu; Wilma Mackay; Ronald J Bosch; Mari Kitahata; Stephen L Boswell; W Christopher Mathews; David R Bangsberg; Jeffrey Martin; Christopher C Whalen; Scott Sieg; Suhrida Yadavalli; Steven G Deeks; Michael M Lederman Journal: JAMA Date: 2006-09-27 Impact factor: 56.272
Authors: Andre J Marozsan; Dawn M Moore; Michael A Lobritz; Erika Fraundorf; Awet Abraha; Jacqueline D Reeves; Eric J Arts Journal: J Virol Date: 2005-06 Impact factor: 5.103
Authors: Eric S Daar; Karen L Kesler; Christos J Petropoulos; Wei Huang; Michael Bates; Alice E Lail; Eoin P Coakley; Edward D Gomperts; Sharyne M Donfield Journal: Clin Infect Dis Date: 2007-07-20 Impact factor: 9.079
Authors: Matthew Bidwell Goetz; Robert Leduc; Jay R Kostman; Ann M Labriola; Yolanda Lie; Jodi Weidler; Eoin Coakley; Michael Bates; Roberta Luskin-Hawk Journal: J Acquir Immune Defic Syndr Date: 2009-03-01 Impact factor: 3.731
Authors: Theodore D Ruel; Moses R Kamya; Pelin Li; William Pasutti; Edwin D Charlebois; Teri Liegler; Grant Dorsey; Philip J Rosenthal; Diane V Havlir; Joseph K Wong; Jane Achan Journal: J Acquir Immune Defic Syndr Date: 2011-01-01 Impact factor: 3.731
Authors: Oon Tek Ng; Oliver Laeyendecker; Andrew D Redd; Supriya Munshaw; Mary K Grabowski; Agnes C Paquet; Mark C Evans; Mojgan Haddad; Wei Huang; Merlin L Robb; Steven J Reynolds; Ronald H Gray; Maria J Wawer; David Serwadda; Susan H Eshleman; Thomas C Quinn Journal: J Infect Dis Date: 2013-08-06 Impact factor: 5.226
Authors: Victoria E Walker-Sperling; Christopher W Pohlmeyer; Rebecca T Veenhuis; Megan May; Krystle A Luna; Allison R Kirkpatrick; Oliver Laeyendecker; Andrea L Cox; Mary Carrington; Justin R Bailey; Roberto C Arduino; Joel N Blankson Journal: EBioMedicine Date: 2017-01-26 Impact factor: 8.143
Authors: Frederic Bertels; Alex Marzel; Gabriel Leventhal; Venelin Mitov; Jacques Fellay; Huldrych F Günthard; Jürg Böni; Sabine Yerly; Thomas Klimkait; Vincent Aubert; Manuel Battegay; Andri Rauch; Matthias Cavassini; Alexandra Calmy; Enos Bernasconi; Patrick Schmid; Alexandra U Scherrer; Viktor Müller; Sebastian Bonhoeffer; Roger Kouyos; Roland R Regoes Journal: Mol Biol Evol Date: 2018-01-01 Impact factor: 16.240